Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:ONS

Oncobiologics (ONS) Stock Price, News & Analysis

Oncobiologics logo

About Oncobiologics Stock (NASDAQ:ONS)

Advanced Chart

Key Stats

Today's Range
$0.84
$1.07
50-Day Range
$0.72
$7.40
52-Week Range
$0.57
$1.53
Volume
18.31 million shs
Average Volume
69,024 shs
Market Capitalization
$61.46 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive ONS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Oncobiologics and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ONS Stock News Headlines

Buffett, Gates and Bezos Quietly Dumping Stocks—Here's Why
Imagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA or Bitcoin, but by owning a simple index fund. It sounds impossible. Yet it happened – just a short time ago. Now a legendary figure says: "Brace yourselves. It's about to happen here, in America. But fair warning – it could be the worst thing that ever happens to you." This story has received little coverage in the press. But if history repeats, it could bump tens of millions of Americans into a 7-figure net worth practically overnight.tc pixel
Are Away Carry-Ons Worth the Hype?
ONS - the Office of National Statistics
See More Headlines

ONS Stock Analysis - Frequently Asked Questions

Oncobiologics (ONS) raised $35 million in an IPO on Friday, May 13th 2016. The company issued 5,800,000 shares at $6.00 per share. Jefferies and Barclays served as the underwriters for the IPO and Cantor Fitzgerald & Co. was co-manager.

Based on aggregate information from My MarketBeat watchlists, some other companies that Oncobiologics investors own include CRISPR Therapeutics (CRSP), Network-1 Technologies (NTIP), Allena Pharmaceuticals (ALNA), Intra-Cellular Therapies (ITCI), Cidara Therapeutics (CDTX), Neuralstem (CUR) and Exelixis (EXEL).

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biological Products, Except Diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:ONS
Previous Symbol
NYSE:ONS
CIK
1649989
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$38.84 million
Net Margins
-464.47%
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
-93.28%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.41
Quick Ratio
0.41

Sales & Book Value

Annual Sales
$3.81 million
Price / Sales
16.13
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($1.36) per share
Price / Book
-0.63

Miscellaneous

Outstanding Shares
72,200,000
Free Float
N/A
Market Cap
$61.46 million
Optionable
Not Optionable
Beta
-0.27
Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

This page (NASDAQ:ONS) was last updated on 9/1/2025 by MarketBeat.com Staff
From Our Partners